Advertisement
Cardiometabolic outcomes and safety vary among different once-weekly glucagon-like peptide-1 receptor agonist treatments

Review Compares Outcomes, Safety for Once-Weekly GLP-1RAs

0
Greater reduction of HbA1c, fasting plasma glucose, body weight for dulaglutide, exenatide, taspoglutide
The combination of effective transmission of knowledge

Med Ed Can Be Improved for High-Value, Cost-Conscious Care

0
Review shows knowledge transmission, reflective practice, supportive environment aid learning
Fewer American families are struggling to pay medical bills

CDC: Fewer Americans Struggling With Medical Bills

0
U.S. report shows 12 million are no longer in families having trouble paying for health care
Kanuma (sebelipase alfa) has been approved by the U.S. Food and Drug Administration as the first treatment for LAL deficiency (Wolman disease or cholesteryl ester storage disease).

FDA Approves Kanuma for Lysosomal Acid Lipase Deficiency

0
For treatment of LAL deficiency, also known as Wolman disease or cholesteryl ester storage disease
Statin treatment is associated with reduced risk of incident cataract development

Statin Treatment Linked to Reduced Risk of Cataracts

0
Simvastatin plus ezetimibe linked to lower risk of cataract development versus placebo
All children should be screened for high cholesterol

AAP: Screen All Children for Cholesterol, Depression, HIV

0
American Academy of Pediatrics guidelines reflect concerns about obesity, suicide
Participation in the endurance competition known as the Ultraman is associated with dramatic alterations in body composition

Endurance Athletes May Suffer Dangerous Metabolic Effects

0
'Ultraman' competitors experience muscle damage and insulin resistance, researchers find
Very old patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) have increased rates of PCI failure

Poor PCI Outcomes Up for Very Old With STEMI

0
However, successful percutaneous coronary intervention benefits all age groups
Nearly half of American adults who should be taking cholesterol-lowering drugs don't

CDC: Too Few Taking Needed Cholesterol-Lowering Drugs

0
Only half who should are using medications to help prevent cardiovascular disease
Large clinical studies that are sponsored by industry are more likely to report favorable outcomes and less likely to report unfavorable outcomes than those sponsored by the National Institutes of Health

Cardiovascular Trial Sponsorship Significantly Impacts Findings

0
Favorable outcomes seven times more likely in industry- versus NIH-sponsored trials